CME accreditation
23rd Pan American Congress of Rheumatology
August 12-15, 2021
Jointly provided by Postgraduate Institute for Medicine and Pan American League of Associations for Rheumatology
TARGET AUDIENCES
This activity is intended for physicians engaged in the care of patients with rheumatology related conditions.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Evaluate and treat patients according to the latest advances in the state of the art
- Identify pathologies according to the different symptoms
- Apply the new best practices shared by the most advanced professionals and experts in the field
- Work collaboratively and efficiently with other members of the healthcare team
- Develop a networking group to exchange experiences and knowledge
TEACHERS
Please view complete faculty
PROGRAM AGENDA
Check the agenda with the registration and break times by clicking here
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Pan American League of Associations for Rheumatology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN MEDICAL EDUCATION FOR DOCTORS
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 21.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.
Miguel Albanese
Consulting fees from AbbVie
Fees for Non-CE services from Mead Laboratories
Daniel Aletaha
Consulting fees from AbbVie, Amgen, Lilly, Merck, Novartis, Pfizer, Roche and Sandoz
Research support from AbbVie, Amgen, Lilly, Novartis, Roche, SoBi and Sanofi
Ana Maria Arredondo Gonzalez
Consulting fees from Janssen and Bristol Meyers Squibb
Fees for Non-CE services from Janssen, Bristol Meyers Squibb, Pfizer, Biopas, Amgen Roche and Lilly
Cecelia Asnal
Consulting fees from Pfizer, Lilly and Abbvie
Joshua Baker
Consulting fees from Bristol Myers Squibb, Burns-White, LLC, Pfizer and CorEvitas
Alejandro Balsa
Consulting fees from Pfizer, Roche, Abbvie, BMS, UCB, MSD, Novartis, Nordic, Sandoz, Kern Pharma, Sanofi, Gilead, Galapagos
Fees for Non-CE services from Pfizer, Roche, Abbvie, BMS, UCB, MSD, Novartis, Nordic, Sandoz, Kern Pharma, Sanofi, Gilead, Galapagos
Wilson Bautista-Molano
Consulting fees from Lilly, Novartis and Pfizer
Mihai Bojinca
Consulting fees from Lilly, Novartis and Pfizer
Fees for Non-CE services from AbbVie, Lilly, Novartis, Pfizer, Sandoz, Krka and Zentiva
Antonio Cachafeiro
Consulting fees from AbbVie, Novartis and Sandoz
Juan Canoso
Royalty from UpToDate (2 chapters)
Loreto Carmona
Contracted research with AbbVie, Gebro Pharma, MSD, Novartis, Pfizer, Roche, Sanofi Aventis, Gruenthal and UCB
Gustavo Citera
Consulting fees from Pfizer, Eli Lilly, Janssen, Abbvie, Amgen and Sandoz
Ines Corbacho
Consulting fees from AbbVie and Scienza
Maria de Los Angeles Correa
Consulting fees from AbbVie and Janssen
Carmen de Cunto
Speaker fees from Biogen, Springer Educational Program
Contracted research fees from Clementia/Ipsen
Cristina Drenkard
Consulting fees from SLE Expert Network
Contracted research fees from Let’s Talk About Lupus Education Program
Doruk Erkan
Royalty from UpToDate
Consulting fees from UCB, Alexion
Fees for Non-CE services from GSK, Aurinia
Contracted research fees from ACR/Eular, NIH, GSK, Exagen, LCTC
Polly Ferguson
Consulting fee from Novartis
Ivan Foeldvari
Contracted research fees to be part of the Phase III nintdeanib study for jSSc
Richard Furie
Consulting fees from GlaxoSmithKline, Aurinia Pharmaceuticals
Adrian Gaser
Consulting fees from Boehringer Ingelheim
Fees for Non-CE services from Boehringer Ingelheim, Biotoscana, Raffio and Bagó
Annelise Goecke
Consulting fees from Janssen, AbbVie, BMS and UCB
Jose Gomez Puerta
Consulting fees from Sanofi and Galápagos
Fees for Non-CE services from AbbVie, Astra Zeneca, BMS, Lilly, GSK, MSD, Pfizer, Roche
Ellen Gravallese
Salary from NEJM for Associate Editor position; Salary from ACR for Presidency and President Elect positions
Royalty from textbook “Rheumatology” and UpToDate
Kristen Hayward
Ownership Interest less than 5% in Abbott Labs, AbbVie, Avanos Medical Inc, Teva Pharmaceuticals
Ownership Interest greater than 5% in Merck
Johanna Hernandez
Consulting fees from Pfizer and AbbVie
Sebastian Herrera Uribe
Consulting fees from Janssen-Cilag, Novartis, Amgen, Bristol Myers Squibb and AbbVie
Fees for Non-CE services from Pfizer, Roche, AbbVie, Janssen-Cilag, Novartis, Amgen and Bristol Myers Squibb
Frederic Houssiau
Consulting fees from GSK, Idorsia and Astra Zeneca
Annamaria Iagnocco
Consulting fees from
AbbVie, MSD, Alfasigma, Celltrion, BMS, Celgene, Eli Lilly, Sanofi Genzyme, Galapagos, Gilead, Novartis and Sobi Inc
Carolina Isnardi
Consulting fees from Bristol Myers Squibb
Contracted research fees from Pfizer, Elea Phoenix, AbbVie and Janssen
David Karp
Contracted research fees from Glaxo Smith Kline, Genentech, Bristol Myers Squibb, UCB Pharma, Eli Lilly and Celgene
Kim Lauper
Consulting fees from Pfizer, Celltrion, Viatris and Gilead-Galapagos
Carlos Lozada
Consulting fees from Pfizer, Aurinia, Novartis and Amgen
Claudia Marques
Consulting fees from Novartis and AbbVie
Iain McInnes
Consulting fees from AbbVie, Astra Zeneca, Amgen, BMS, Cabaletta, Causeway Therapeutics, Compugen, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, Sanofi and UCB
Contracted research fees from BMS, Compugen, GSK, Eli Lilly, Janssen, Novartis, Pfizer and UCB
Ownership interest less than 5% in Causeway Therapeutics, Cabaletta and Compugen
Licia Mota
Consulting fees from Boehringer Ingelheim, AbbVie, Janssen, Pfizer and Amgen
Fees for Non-CE Services from AbbVie, Pfizer, Roche, Janssen, Boehringer Ingelheim and Sandoz
Jose Luis Neyro
Contracted research fees from Stada and Amgen
Eduardo S. Paiva
Consulting fees from Janssen and Amgen
Fee for Non-CE services from Pfizer
Guillermo Pons-Estel
Consulting fees from Pfizer and GSK
Fees for Non-CE services from Janssen, Pfizer and GSK
Contracted research fees from Janssen
Chris Ritchlin
Consulting fees from Amgen, AbbVie, UCB, Lilly, Janssen, Novartis, Bristol Myers Squibb and Sun
Brad Rovin
Consulting fees from Aurinia and GSK
Percival Sampaio
Consulting fees from Boehringer, Lilly, Novartis and Pfizer
Fees for Non-CE services from AbbVie, Boehringer, Lilly, Novartis and UCB
Pedro Santos-Moreno
Consulting fees from Boehringer, Lilly, Pfizer, Janssen, Novartis, Biopas-UCB
Fees for Non-CE services from Lilly, Pfizer, Janssen, Novartis, Amgen and Biopas-UCB
Contracted research fees from Janssen, Pfizer and Bristol Myers Squibb
Fernando Sommerfleck
Consulting fees from AbbVie and Janssen
Fees for Non-CE services from AbbVie, Janssen and Novartis
Enrique Soriano
Consulting fees from AbbVie, Amgen, Janssen, Lilly, Novartis and Pfizer
Fees for Non-CE services from AbbVie, Amgen, Janssen, Lilly, Novartis and Pfizer
Lilith Stange
Consulting fees from Novartis, Sandoz, Roche and AbbVie
Fees for Non-CE services from Fresenius Kabi, AbbVie, Roche, Pfizer, Novatis, Eurofarma and Biopas
Flavio Sztajnbok
Consulting fees from Novartis
Fees for Non-CE services from AbbVie, Alexion and Novartis
Teresa Terreri
Consulting fees from Novartis
Gloria Vasquez
Fees for Non-CE Services from AbbVie, Janssen and Roche
Dan Zhao
Royalty from UpToDate
Consulting fees from Novartis
Contracted research fees from BMS
Dina Arrieta
Consulting fees from AbbVie and Novartis
Cesar Pacheco
Consulting fees from AbbVie, Novartis and Eli Lilly
Contracted research fees for AbbVie, Eli Lilly and Pfizer
Juan Jose Scali
Consulting fees from AbbVie, Pfizer, Bago, Montpellier and TRB Pharma
Alejandro Nitsche
Medical Advisor at Bago Laboratories of Argentina
Luis Fernando Luque
Ownership interest greater than 5% in Adhera Health Inc (Co-founder and Chief Scientific Officer)
John Cush
Consulting fees from AbbVie, Novartis, BMS and Amgen
Carlos Enrique Toro Gutierrez
Consulting fees from Janssen, Roche, Novartis, Boehringer Ingelheim
Fees for Non-CE services from AbbVie and Biopas
All other faculty have nothing to disclose.
ORAL PRESENTATIONS OF ABSTRACTS
The presenters of the submitted abstracts have nothing to disclose.
PLANNERS AND MANAGERS
The PIM planners and managers have nothing to disclose. The planners and managers of the Pan American League of Rheumatology Associations have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
